Skip to product information
1 of 4
Wellness · Women's Health ·PCOS Fertility

PCOS Fertility

PCOS Fertility

60 Vegan Capsules · Myo-Inositol + D-Chiro-Inositol 3.6:1 · Nutraceutical

Evidence: High Vegan Inositol 3.6:1 Ratio Active Folate (L-5-MTHF)

This is for you if

  • Trying to conceive with PCOS and irregular or anovulatory cycles
  • Diagnosed with PCOS and prioritising follicular and ovulatory function
  • Looking for an evidence-based alternative to Metformin without the GI side effects

What changes, and when

  • Wk 4–6 Cycle regularity
  • Wk 8–12 Insulin sensitivity (HOMA-IR)
  • Wk 12+ Ovulation rate

Key Actives per Serving (2 Capsules)

  • Myo-Inositol Insulin sensitiser 1100 mg
  • D-Chiro-Inositol Ovarian androgen modulator 300 mg
  • L-5-MTHF Active folate 232 mcg

Key clinical outcomes supported

  • → Restored ovulatory cycles in anovulatory PCOS
  • → Improved oocyte quality and follicular maturation
  • → Reduced insulin resistance (HOMA-IR)
  • → Lower free testosterone and DHEAS
Regular price ₹1,650.00
Regular price MRP Sale price ₹1,650.00
/ 60 Capsule · 30 servings · ₹55 per serving
Taxes included.
Quantity
View full details
01

Ingredients & Supplement Facts

Ingredient & Form Dose Rationale
Inositol/ Myo-inositol 1100mg

Unfer et al. 2017 meta-analysis: improved ovulation and pregnancy rates in PCOS. Costantino et al. 2009: 4 g/day restored ovulatory cycles vs placebo.

D-Chiro-Inositol 300mg

Nestler et al. 1999: improved ovulation and reduced androgens in PCOS at 1200 mg/day. Genazzani et al. 2014: dose-dependent effect on ovulatory function.

L-Methyltetrahydrofolate 232mcg

Pietrzik et al. 2010: comparable plasma folate response to folic acid without unmetabolised folic acid accumulation. Obeid et al. 2013: preferred form in MTHFR C677T variants.

Nutritional Information
02

Dosage & Rationale

2
Capsule
Daily · 2 capsules · post-lunch with food

Inositol absorption is dose-dependent and improves with a meal containing fat and protein — post-lunch dosing avoids GI sensitivity and aligns with fed-state pharmacokinetics. Splitting the daily dose into two capsules taken together maintains the 3.6:1 myo-to-D-chiro ratio in plasma at peak absorption. Consistent daily use over 12+ weeks is what published RCTs measure.

Loading Period: 8–12 weeks for ovulatory response

Inositol therapy works cumulatively. Cycle regularity often improves first; ovulation rate and oocyte quality follow. Consistent daily use is more important than timing precision.

03

Batch & Quality Details

Batch Number
Manufactured
Expiry
Status ● Archived
04

Third-Party Testing — Batch

05

Safety & Competition Notes

  • No WADA Prohibited Substances
  • No Stimulants
  • Vegan (Hypromellose capsule shell)
  • Caffeine-free

Take as directed with food. Generally well-tolerated. Consult your healthcare provider before use if you are pregnant, lactating, on prescription medication, or have any chronic medical condition.

06

Evidence Dossier

Overall Evidence Grade HIGH · Multiple RCTs in PCOS Fertility Populations

Inositol therapy for PCOS is one of the most extensively studied nutritional interventions in reproductive endocrinology. The 3.6:1 ratio is supported by clinical evidence for fertility-focused protocols, distinct from the 40:1 ratio for general metabolic management.

The clinical goal: restoration of ovulatory function through dual-pathway action on systemic insulin sensitivity (myo) and ovarian androgen synthesis (D-chiro), with active folate (L-5-MTHF) supporting oocyte quality.

Ingredient Mechanism Evidence Key Notes
Inositol/ Myo-inositol Restores intracellular inositol phosphoglycan availability; improves insulin sensitivity and ovarian FSH response ● High
D-Chiro-Inositol Direct modulator of ovarian theca cell androgen synthesis; insulin signalling cofactor; complementary to myo-inositol in PCOS protocols ● High
L-Methyltetrahydrofolate Bypasses MTHFR enzyme conversion required by synthetic folic acid; supports homocysteine clearance, DNA methylation, and neural tube development ● High
07

Condition Rationale — Why These Nutrients for PCOS

PCOS-related infertility has three distinct mechanisms. This formulation targets each specifically.

  • Pathway 1 — Ovarian Insulin Signalling. Myo-Inositol acts as a second messenger in the FSH signalling pathway within granulosa cells.
    Myo-Inositol 1100mg
  • Pathway 2 — Ovarian Androgen Synthesis. D-Chiro-Inositol modulates ovarian theca cell androgen production directly.
    D-Chiro-Inositol 300mg
  • Pathway 3 — Folate Status & Preconception Readiness. L-5-MTHF bypasses the MTHFR conversion step.
    L-5-MTHF 232mcg
08

What Each Ingredient Does

01 · Inositol/ Myo-inositol

Myo-Inositol — The insulin signalling sugar

Myo-Inositol acts as a second messenger in the FSH signalling pathway within the ovary's granulosa cells, supporting follicular response and oocyte quality. It also improves systemic insulin sensitivity, addressing the metabolic root of PCOS-related infertility.

02 · D-Chiro-Inositol

D-Chiro-Inositol — The ovarian androgen modulator

D-Chiro-Inositol works directly inside the ovary to lower the elevated androgen production from theca cells that blocks ovulation in PCOS. The 3.6:1 myo-to-D-chiro ratio in this formulation reflects the higher relative D-chiro requirement of fertility-focused protocols.

03 · L-Methyltetrahydrofolate

L-5-MTHF — Active folate, ready-to-use

L-5-Methyltetrahydrofolate is the bioactive form of folate that the body uses directly, bypassing the MTHFR conversion required by synthetic folic acid. The 232 mcg dose delivers 220 mcg DFE — clinically relevant for oocyte maturation and early pregnancy regardless of MTHFR genotype.

09

Frequently Asked Questions

010

Verified Reviews

PRODUCT QUESTIONS

Have a clinical, formulation, or dosing question that the page does not answer? Write to wecare@unived.com.

A person from the team responds, usually within a working day.